ASTELLAS PHARMA UNSP.ADR (YPHA) - Total Assets
Based on the latest financial reports, ASTELLAS PHARMA UNSP.ADR (YPHA) holds total assets worth €3.34 Trillion EUR (≈ $3.90 Trillion USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ASTELLAS PHARMA UNSP.ADR - Total Assets Trend (2022–2025)
This chart illustrates how ASTELLAS PHARMA UNSP.ADR's total assets have evolved over time, based on quarterly financial data. Also see YPHA market cap overview for the company's overall valuation and market capitalisation.
ASTELLAS PHARMA UNSP.ADR - Asset Composition Analysis
Current Asset Composition (March 2025)
ASTELLAS PHARMA UNSP.ADR's total assets of €3.34 Trillion consist of 36.0% current assets and 64.0% non-current assets. Review ASTELLAS PHARMA UNSP.ADR (YPHA) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.6% |
| Accounts Receivable | €632.52 Billion | 18.9% |
| Inventory | €297.26 Billion | 8.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.12 Trillion | 33.7% |
| Goodwill | €415.21 Billion | 12.4% |
Asset Composition Trend (2022–2025)
This chart illustrates how ASTELLAS PHARMA UNSP.ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for ASTELLAS PHARMA UNSP.ADR for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ASTELLAS PHARMA UNSP.ADR's current assets represent 36.0% of total assets in 2025, a decrease from 39.6% in 2022.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2025, down from 13.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 38.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 33.7% of total assets.
ASTELLAS PHARMA UNSP.ADR Competitors by Total Assets
Key competitors of ASTELLAS PHARMA UNSP.ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
ASTELLAS PHARMA UNSP.ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.13 | 1.10 | - |
| Quick Ratio | 0.85 | 0.86 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €139.74 Billion | €109.65 Billion | - |
ASTELLAS PHARMA UNSP.ADR - Advanced Valuation Insights
This section examines the relationship between ASTELLAS PHARMA UNSP.ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -6.4% |
| Total Assets | €3.34 Trillion |
| Market Capitalization | $19.55 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ASTELLAS PHARMA UNSP.ADR's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ASTELLAS PHARMA UNSP.ADR's assets decreased by 6.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ASTELLAS PHARMA UNSP.ADR (2022–2025)
The table below shows the annual total assets of ASTELLAS PHARMA UNSP.ADR from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €3.34 Trillion ≈ $3.90 Trillion |
-6.44% |
| 2024-03-31 | €3.57 Trillion ≈ $4.17 Trillion |
+45.31% |
| 2023-03-31 | €2.46 Trillion ≈ $2.87 Trillion |
+5.32% |
| 2022-03-31 | €2.33 Trillion ≈ $2.73 Trillion |
-- |
About ASTELLAS PHARMA UNSP.ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms… Read more